Serotonin Mechanisms in Chemotherapy-Induced Emesis in Cancer Patients

Oncology (Switzerland)

Volumn 53, Issue 1, 1996, Pages 18-25

  Cubeddu, Luigi X ^a  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

5 Hydroxyindoleacetic acid; Cancer chemotherapy; Cisplatin; Emesis; Serotonin

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANTIEMETIC AGENT; APOMORPHINE; BEMESETRON; CARBOPLATIN; CHLORMETHINE; CHOLECYSTOKININ; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FENCLONINE; GRANISETRON; IFOSFAMIDE; LOPERAMIDE; MELPHALAN; ONDANSETRON; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; TROPISETRON; ZACOPRIDE; ZATOSETRON;

ANTIEMETIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONFERENCE PAPER; ENTEROCHROMAFFIN CELL; HUMAN; PRIORITY JOURNAL; SEROTONIN RELEASE; VOMITING;

ANTINEOPLASTIC AGENTS; CISPLATIN; HUMANS; NEOPLASMS; SEROTONIN; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0029811856     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227636     Document Type: Article

References (34)

1. Costall B, Domency AM, Naylor RJ, Tattersali FD, Tvcrs MB: 5-Hydroxytryptamine M-re-ccptor antagonism to prevent cisplatinum-in-duced cmesis, Neuropharmacologv 1986:25: 959.
2. Miner WD, Sanger GJ: Inhibition of cisplatin-induccd vomiting by selective 5-hydroxytrvp-taminc M-receptor antagonism, Br J Pharmacol 1986:88:497-499.
3. Andrews PRL: 5-HTj receptor antagonists and antiemesis; in King F, Jones B, Sanger G (eds): 5-Hydroxytryptamine-3 Receptors, Boca Raton, CRC Press, 1994, pp 255-317.
4. Cassidy J, Raina V, Lewis C, Adams L, Soukop M, Rapcpport WG, Zussman BD, Kaye SB: Pharmacokinetics and antiemetic efficacy of BRL 43694, a new selective 5-HTj antagonist, Br J Cancer 1988:58:651-653.
5. Viner CV, Selby PJ, Zulian GB, Gore MF„ Butcher MW, Wooton CM, McElwain TJ: Ondansetron - a new safe and effective anti-cmct-ic in patients receiving high-dose melphalan, Cancer Chcmother Pharmacol 1990:24:449-453.
6. Stott JRR, Barnes GR, Wright RJ, Ruddock CJS: The effects on motion sickness and oculomotor function of GR-38032F, a 5-I ITi receptor antagonist with anti-emetic properties, Br J Clin Pharmacol 1989;27:1-11.
7. Bermudez J, Boyle EA, Miner WD, Sanger GJ: The anticmetic potential of the 5-hydroxytryp-tamine receptor antagonist BRL 43694, Br J Cancer 1988:58:644-650.
8. Cubcddu LX, Hoffmann IS, Fuenmayor NT, Finn AL: Efficacy of ondansetron (GR38032F) and the role of serotonin in cisplatin-induced nausea and vomiting, N Engl J Med 1990:322: 810-816.
9. Cubcddu LX, Hoffmann IS, Fuenmayor NT, MalaveJJ: Changes in serotonin metabolism in cancer patients: Its relationship to nausea and vomiting induced by chemotherapeutic drugs, Br J Canccr 1992:66:198-203.
10. Cubcddu LX, Hoffmann IS: Participation of serotonin on early and delayed emesis induced by initial and subequent cycles of cisplatinum-based chemotherapy: Effects of dexamethasone and metoclopramide, J Clin Pharmacol 1993: 33:691-697.
11. Cubcddu LX: The role of serotonin in chemotherapy-induced emesis in canccr patients; in Diaz Rubio E, Martin M (eds): Antiemetic Therapy: Current Status and Future Prospects, Madrid, Creaciones Elba, 1994, pp 40-55.
12. Wilder-Smith OHG, Borgeal A, Chappuis P: Urinary serotonin metabolite excretion during cisplatin chemotherapy, Cancer 1993:72: 2239-2241.
13. Cubcddu LX, Garcia I, O'Connor DT, Parmer RJ: Effects of dacarbazinc, nitrogen mustard and cyclophosphamide on plasma chromo-granin A and urinary vhydroxyindoleacetic acid in cancer patients, Proc XII Ini Congr Pharmacol, Can J Physiol Pharmacol 1994; 72(suppl I):457, abstr P13.24.38.
14. Cubeddu LX, Hoffman IS: Mechanisms of the emetic response to chemotherapy and of the antiemetic action of 5-H Ti-receptor antagonists: Clinical studies; in Vanhouttc PM, Sax-ena PR, Paoletti R, Brunello N, Jackson AS, (eds): Serotonin: From Cell Biology to Pharmacology and Therapeutics, London, Kluwcr, 1994, pp 171-178.
15. Alfieri BA, Cubeddu LX: EfTccts of inhibition of serotonin synthesis on 5-hydroxyindoleacet-ic acid, in healthy subjects, J Clin Pharmacol 1994:34:153-157.
16. Bertaccini G: Tissue 5-hydroxytryptamine and urinary 5-hvdroxyindoleacetic acid after partial or total removal of the gastrointestinal tract in the rat, J Physiol 1960:153:239-249.
17. Bertaccini G, Chieppa S: Urinary excretion of 5-hydroxyindolcacetic acid after removal of the large intestine in man, Lancet 1960;278:881-882.
18. Rosenberg JC, Davis R, Moran WH, Zimmerman B: Serum serotonin concentration and urinary 5-hydroxyindoleacetic acid excretion following intestinal obstruction and resection, Fed Proc 1959; 18:503.
19. Feldberg W, Toll CC: Distribution of 5-hydroxytryptamine (serotonin enteramine) in the wall of the digestive tract, J Physiol (Lond) 1953;119:352-362.
20. Resnick RH, Gray SJ: Distribution of serotonin (5-hydroxytryptamine) in the human gastrointestinal tract, Gastroenterology 1961;41: 119-121.
21. Schworer H, Rackc K, Kilbinger H: Cisplatin increases the release of 5-hydroxytryptamine from the isolated vascularly perfused small intestine of the guinea pig: Involvement of 5-HTj receptors, Naunyn Schmiedcbergs Arch Pharmacol 1991;344:143-149.
22. Fukui H, Yamamoto M, Anto T, Sasaki S, Sato S: Increase in serotonin levels in the dog ileum blood by cisplatin as measured by microdialysis, Neuropharmacology 1993:32:959-968.
23. Gunning SJ, Hagan RM, Tyers MB: Cisplatin-induced biochemical and histological changes in the small intestine of the ferret, Br J Pharmacol 1987:90:135.
24. Barnes NM, Ge J, Jones WG, Naylor RJ, Rudd JA: Cisplatin-induced emesis: Preliminary results of indicative changes in plasma levels of 5-hydroxytryptamine, Br J Canccr 1990:62: 862-864.
25. Cubeddu LX, O'Connor DT, Parmer RJ: Cis-platin-induccd vomiting, increases in plasma chromogranin A and in serotonin metabolism, Proc XII Int C'ongr Pharmacol, Can J Physiol Pharmacol 1994:72(suppl I): 453, abstr P13.24.14.
26. Barnes JM, Barnes NM, Costall B, Naylor RJ, Tattersall FD: Reserpine, para-chlorophcnylal-anine and flenfluramine antagonise cisplatin-induced emesis in the ferret, Neuropharmacology 1988;27:783-790.
27. Costall B, Domeney AM, Naylor RJ, Owera-Atepo JB, Rudd JA, Tattersall FD: Fluphcna-zine, ICS 205-930 and /./-fenfluramine differentially antagonize drug-induced emesis in ferret, Neuropharmacology 1990:29:769-787.
28. Andrews PRL, Bhandari P, David CJ: Plasticity and modulation of the emesis reflux; in Bianchhi Al, Grelot L, Miller AD, King GL (eds): Mechanisms and Control of Emesis, Col-loquc INSERM, London, Libbey Eurotext,1992, vol 223, pp 275-284.
29. Alfieri AB, Cubeddu LX: Inhibition of serotonin synthesis prevents cisplatin-induced nausea and vomiting in canccr patient, Proc XII Int C'ongr Pharmacol, Can J Physiol Pharmacol 1994;72(suppl I):242, abstr P6.3.31.
30. Hawthorn J, Ostler KJ, Andrews PLR: The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cisplatin in the ferret, Q J Exp Physiol 1988;73:7-13.
31. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL: Antagonism of serotonin S3 receptors prevents the nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens, J Clin Oncol 1990:8:1721-1727.
32. Cubeddu LX, Pendergrass K, Thomas R, Martin Y, Burton G, Meshad M, Galvin D, Ciocio-Ia AA: Efficacy of oral ondansetron, a selective antagonist of 5-HT; receptors, in the treatment of nausea and vomiting associated with cyclo-phcsphamidc-bascd chemotherapies, Am J Clin Oncol 1994:17:137-146.
33. Hcsketh P: Management of cisplatin-induced delayed emesis, Oncology 1996;53(suppl 1); 73-77.
34. Ossi M, Anderson E, Freeman A: The role of 5-HTi rcccptor antagonists in the control of cis-platin-induccd delayed emesis, Oncology 1996; 53(suppl 1): 78-85.